A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more. 

Instylla's Embrace Hydrogel Embolic System minimizes bleeding risks during the embolization of hypervascular tumors in the peripheral arteries.

The FTC is working to stop Edwards Lifesciences from completing its acquisition of JenaValve. Edwards, however, is not backing down.

Customers with these devices on hand are asked to return them right away. No serious injuries have been reported at this time, but the presence of residual particulates can lead to such side effects as pulmonary embolism and deep vein thrombosis.

Because of this risk, which has been associated with 120 serious injuries, Boston Scientific is updating the instructions for use of several Watchman access systems.

Boston Scientific manufactured these devices from 2002 to 2021, and approximately 354,000 are still in use. It is recommended that clinicians look for early signs of this issue during scheduled follow-up appointments.

Researchers reviewed data from more than 1,300 patients who underwent both CCTA and TEE after undergoing LAAO. The two modalities were comparable in many ways, but cardiac CT was linked to a few key benefits.

Most patients are first diagnosed with heart failure in an emergency room or hospital, when their symptoms are already severe. This advanced algorithm could change all that by opening up screening to many more patients. 

Wearable health devices outfitted with AI seem poised to transition from consumer novelties to an integral layer of U.S. public-health intelligence. 

Ultromics plans to use the new funds to help expand its presence throughout the United States. In addition, the company is focused on developing additional AI-enabled software offerings.